Marker Therapeutics shareholders approved charter amendment boosting authorized common stock to 130 million shares

• Marker Therapeutics held its annual shareholder meeting on May 1, 2026.
• Shareholders adopted an amendment to increase authorized Common Stock to 130,000,000 shares from 30,000,000 shares; company reported this approval, without stating that any new shares have been issued.
• A separate charter amendment to revise voting threshold for future increases or decreases of Common Stock failed to win approval.
• Shareholders ratified CBIZ CPAs P.C. as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.
• Shareholders also authorized adjournment of meeting if support for authorized-share increase had been insufficient.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-054940), on May 04, 2026, and is solely responsible for the information contained therein.